@danilo I think you're overestimating what pharma spends on research and regulatory work, but ok, let's ignore them.
All these other sectors with enormous growth potential + low and falling infrastructure costs still don't react the same way to interest rates. It's not the interest. It's the lack of counterbalancing power.